Trade-Off Between Lipid-Lowering Therapy and Costs in Patients With Cardiovascular Disease

Circ J. 2018 Sep 25;82(10):2481-2482. doi: 10.1253/circj.CJ-18-0811. Epub 2018 Aug 7.

Authors

Hideki Ishii¹, Toyoaki Murohara¹

Affiliation

¹ Department of Cardiology, Nagoya University Graduate School of Medicine.

PMID: 30089745
DOI: 10.1253/circj.CJ-18-0811

No abstract available

Publication types

Editorial
Comment

MeSH terms

Cardiovascular Diseases*
Coronary Artery Disease*
Cost-Benefit Analysis
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Japan
Lipids
Proprotein Convertase 9

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
PCSK9 protein, human
Proprotein Convertase 9